NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 318 filers reported holding NOVOCURE LTD in Q2 2022. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,977,453 | -62.3% | 7,862,381 | -3.2% | 0.00% | -55.6% |
| Q2 2023 | $337,022,212 | -32.7% | 8,121,017 | -2.4% | 0.01% | -40.0% |
| Q1 2023 | $500,660,749 | -10.3% | 8,324,921 | +9.5% | 0.02% | -11.8% |
| Q4 2022 | $557,874,846 | -0.5% | 7,605,656 | +3.1% | 0.02% | -10.5% |
| Q3 2022 | $560,727,000 | +10.0% | 7,379,945 | +0.6% | 0.02% | +18.8% |
| Q2 2022 | $509,654,000 | -8.6% | 7,333,151 | +8.9% | 0.02% | +6.7% |
| Q1 2022 | $557,787,000 | +11.1% | 6,732,513 | +0.6% | 0.02% | +15.4% |
| Q4 2021 | $502,237,000 | -35.7% | 6,689,356 | -0.5% | 0.01% | -40.9% |
| Q3 2021 | $781,089,000 | -46.0% | 6,723,680 | +3.1% | 0.02% | -45.0% |
| Q2 2021 | $1,446,218,000 | +70.3% | 6,519,780 | +1.5% | 0.04% | +60.0% |
| Q1 2021 | $849,251,000 | -15.3% | 6,424,960 | +10.8% | 0.02% | -21.9% |
| Q4 2020 | $1,003,055,000 | +50.8% | 5,796,680 | -3.0% | 0.03% | +28.0% |
| Q3 2020 | $665,223,000 | +160.9% | 5,976,306 | +39.0% | 0.02% | +150.0% |
| Q2 2020 | $254,975,000 | -33.2% | 4,299,747 | -24.2% | 0.01% | -47.4% |
| Q1 2020 | $381,865,000 | -21.0% | 5,670,686 | -1.1% | 0.02% | 0.0% |
| Q4 2019 | $483,146,000 | +9.1% | 5,733,317 | -3.2% | 0.02% | 0.0% |
| Q3 2019 | $442,834,000 | +26.1% | 5,921,834 | +6.6% | 0.02% | +26.7% |
| Q2 2019 | $351,218,000 | +51.8% | 5,554,632 | +15.6% | 0.02% | +50.0% |
| Q1 2019 | $231,423,000 | +44.1% | 4,804,258 | +0.2% | 0.01% | +25.0% |
| Q4 2018 | $160,592,000 | -35.5% | 4,796,688 | +1.0% | 0.01% | -27.3% |
| Q3 2018 | $248,897,000 | +72.1% | 4,749,934 | +2.8% | 0.01% | +57.1% |
| Q2 2018 | $144,623,000 | +75.8% | 4,620,546 | +22.4% | 0.01% | +75.0% |
| Q1 2018 | $82,279,000 | +7.0% | 3,774,269 | -0.8% | 0.00% | 0.0% |
| Q4 2017 | $76,882,000 | -1.4% | 3,806,096 | -3.1% | 0.00% | 0.0% |
| Q3 2017 | $77,940,000 | +18.8% | 3,926,454 | +3.5% | 0.00% | +33.3% |
| Q2 2017 | $65,622,000 | +136.5% | 3,793,118 | +10.7% | 0.00% | +50.0% |
| Q1 2017 | $27,746,000 | +86606.2% | 3,425,517 | +84376.4% | 0.00% | – |
| Q4 2016 | $32,000 | -23.8% | 4,055 | -16.5% | 0.00% | – |
| Q3 2016 | $42,000 | -38.2% | 4,857 | -16.6% | 0.00% | – |
| Q2 2016 | $68,000 | +1033.3% | 5,827 | +1233.4% | 0.00% | – |
| Q1 2016 | $6,000 | – | 437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |